IP Library Granted Patent US 11,807,874
Granted Patent B2
US 11,807,874 · App. 17/672,542 · Granted Nov 7, 2023

P450-BM3 variants with improved activity

Inventors: Robert Osborne (Raleigh, NC); Vesna Mitchell (Santa Clara, CA); Khin Yu Naing Htwe (Daly City, CA); Xiyun Zhang (Fremont, CA); Erika M. Milczek (New York, NY); Jeffrey C. Moore (Westfield, NJ)
Assignee: Codexis, Inc.
C12N9/0071C07K14/80C12N9/0042C12P13/001C12Y114/14001C12Y106/02004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,807,874
App. No.
17/672,542
Granted
Nov 7, 2023
Kind
B2
Abstract

The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.

Claims (3)

1. A recombinant cytochrome P450-BM3 variant comprising the amino acid sequence of SEQ ID NO: 54, wherein said recombinant cytochrome P450-BM3 variant has cytochrome P450-BM3 activity.

2. The recombinant cytochrome P450-BM3 variant of claim 1 , wherein said variant oxidizes at least three organic substrates.

3. The recombinant cytochrome P450-BM3 variant of claim 2 , wherein the at least three organic substrates are selected from the group consisting of nifedipine, propranolol, verapamil, and diclofenac.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (6)
Continuation 15931310 · May 13, 2020
Continuation 16131252 · Sep 14, 2018
Continuation 15619176 · Jun 9, 2017
Division 14794249 · Jul 8, 2015
Provisional Application 62022442 · Jul 9, 2014
Related Publication 20220169994A1 · Jun 2, 2022
Cited By (1)
US 12,365,882